araag2/HINT huggingface dataset:
Clinical trial NCT00507507 (phase 2, status: completed)
Conditions: chronic hepatitis b
ICD codes: B18.0, B18.1, B18.2, B18.8, B18.9
Drugs: tenofovir df, ftc, placebo
SMILES: [H][C@@](C)(CN1C=NC2=C(N)N=CN=C12)OCP(=O)(OCOC(=O)OC(C)C)OCOC(=O)OC(C)C, NC1=NC(=O)N(C=C1F)[C@@H]1CS[C@H](CO)O1, CN1C(=O)C=C(N2CCC[C@@H](N)C2)N(CC2=C(C=CC=C2)C#N)C1=O
Eligibility criteria:

        Inclusion Criteria:

          -  Chronic HBV infection, defined as positive serum HBsAg for at least 6 months or HBsAg
             positive > 3 months and positive for immunoglobulin G antibody against hepatitis B
             core antigen

          -  18 through 69 years of age, inclusive

          -  Hepatitis B e antigen (HBeAg) positive

          -  HBV DNA ≥ 10^8 copies/mL

          -  ALT ≤ the upper limit of the normal range (ULN)

          -  Willing and able to provide written informed consent

          -  Negative serum beta-human chorionic gonadotropin (for females of childbearing
             potential only)

          -  Calculated creatinine clearance ≥ 70 mL/min

          -  Hemoglobin ≥ 10 g/dL

          -  Neutrophils ≥ 1,500/mm^3

          -  No prior oral HBV therapy (eg, nucleotide and/or nucleoside therapy or other
             investigational agents for HBV infection)

        Exclusion Criteria:

          -  Pregnant women, women who were breast feeding, or who believed they may have wished to
             become pregnant during the course of the study

          -  Males and females of reproductive potential unwilling to use an effective method of
             contraception during the study

          -  Decompensated liver disease defined as direct (conjugated) bilirubin > 1.2 x ULN,
             prothrombin time > 1.2 x ULN, platelets < 150,000/mm^3, serum albumin < 3.5 g/dL, or
             prior history of clinical hepatic decompensation (eg, ascites, jaundice,
             encephalopathy, or variceal hemorrhage)

          -  Received interferon (pegylated or not) therapy within 6 months of the screening visit

          -  Alpha-fetoprotein > 50 ng/mL

          -  Evidence of hepatocellular carcinoma

          -  Coinfection with hepatitis C virus (by serology), HIV, or hepatitis D virus

          -  Significant renal, cardiovascular, pulmonary, or neurological disease

          -  Received solid organ or bone marrow transplantation

          -  Was currently receiving therapy with immunomodulators (eg, corticosteroids, etc.),
             investigational agents, nephrotoxic agents, or agents susceptible of modifying renal
             excretion

          -  Had proximal tubulopathy

          -  Known hypersensitivity to the study drugs, the metabolites, or formulation excipients
Clinical trial NCT01494753 (phase 2, status: completed)
Conditions: primary open angle glaucoma
ICD codes: H40.1130, H40.1131, H40.1132, H40.1133, H40.1134, H40.1110, H40.1111
Drugs: t2345, prostaglandin
SMILES: CC(C)OC(=O)CCC\C=C/C[C@H]1[C@@H](O)C[C@@H](O)[C@@H]1CC[C@@H](O)CCC1=CC=CC=C1
Eligibility criteria:

        Inclusion Criteria:

          -  Untreated bilateral newly diagnosed patients with primary open angle glaucoma

        Exclusion Criteria:

          -  Any ocular hypertension other than chronic open angle glaucoma
Clinical trial NCT01082939 (phase 2, status: completed)
Conditions: chronic lymphocytic leukemia
ICD codes: C91.11, C91.12, C91.10
Drugs: fludarabine, cyclophosphamide, alemtuzumab, rituximab
SMILES: ClCCN(CCCl)P1(=O)NCCCO1, ClCCN(CCCl)P1(=O)NCCCO1, N[C@@H](CCCNC(N)=N)C(O)=O, ClCCN(CCCl)P1(=O)NCCCO1
Eligibility criteria:

        Inclusion Criteria:

          1. All patients must have been diagnosed with CLL by immunophenotyping and flow cytometry
             analysis of blood or bone marrow demonstrating a monoclonal population of CD5 and CD19
             positive cells.

          2. All patient must have been previously treated with chemotherapy.

          3. All patients with Rai stage III-IV are eligible for treatment with this protocol. - OR
             - All patients with Rai stage 0-II who meet one or more indication for treatment as
             defined by the NCI-sponsored Working Group are eligible for treatment with this
             protocol.

          4. All patients must have a Zubrod performance status of 0-3.

          5. All patients must have adequate renal and hepatic function (serum creatinine <2mg/dL;
             total bilirubin <2.5mg/dL). Patients with renal or liver dysfunction due to organ
             infiltration by lymphocytes may be eligible after discussion with the Principle
             Investigator and appropriate dose adjustment considered.

          6. Patients may not receive concurrent chemotherapy, radiotherapy, or immunotherapy.
             Localized radiotherapy to an area not compromising bone marrow function does not
             apply, nor do hematopoietic growth factors such as erythropoietin, Granulocyte
             colony-stimulating factor (G-CSF or GCSF, GM-CSF etc).

          7. Patients must not have untreated or uncontrolled life-threatening infection.

          8. Patients must sign informed consent.

        Exclusion Criteria:

        1. None
Clinical trial NCT01039675 (phase 2, status: completed)
Conditions: pulmonary disease, chronic obstructive
ICD codes: J44.9, J44.1, J44.0
Drugs: 500mcg/25mcg once daily, placebo once daily
SMILES: OCC1=C(O)C=CC(=C1)[C@@H](O)CNCCCCCCOCCOCC1=C(Cl)C=CC=C1Cl, CN1C(=O)C=C(N2CCC[C@@H](N)C2)N(CC2=C(C=CC=C2)C#N)C1=O
Eligibility criteria:

        Inclusion Criteria:

          -  A signed and dated written informed consent prior to study participation

          -  Males or females of non-childbearing potential

          -  40 or more years of age

          -  COPD diagnosis

          -  10 pack-years history or greater of cigarette smoking

          -  Post-bronchodilator FEV1/FVC ratio of 0.70 or less

          -  Post-bronchodilator FEV1 of 80% or less of predicted normal

        Exclusion Criteria:

          -  Current diagnosis of asthma

          -  Other significant respiratory disorders besides COPD, including alpha-1 deficiency

          -  Previous lung resection surgery

          -  Significant abnormalities in chest x-ray presentation

          -  Use of oral steroids, antibiotics or hospitalization for a COPD exacerbation within 3
             motnhs prior screening

          -  Any significant disease that would put subject at risk through study participation

          -  BMI greater than 35

          -  Pacemaker

          -  Significantly abnormal ECG, Holter, or clinical lab finding (including Hepatitis B or
             C)

          -  Cancer

          -  Allergy or hypersensitivity to anticholinergics or inhaler excipients

          -  Diseases that would contra-indicate the use of anticholinergics

          -  Use of oral corticosteroids within 6 weeks of screening

          -  Use of long-acting beta-agonists within 48 hours of screening

          -  Use of tiotropium within 14 days of screening

          -  Use of theophyllines or anti-leukotrienes within 48 hours of screening

          -  Use of short-acting bronchodilators within 4 hours of screening

          -  Use of investigational medicines within 30 days of screening

          -  Use of high dose inhaled corticosteroids

          -  Use of long-term oxygen therapy, CPAP or NIPPV

          -  Previous use of GSK573719 or GW642444
Clinical trial NCT00589186 (phase 2, status: unknown status)
Conditions: head and neck cancer
ICD codes: C76.0, C47.0, C49.0, C77.0, D17.0, D21.0, D36.11
Drugs: celecoxib
SMILES: COC1=CC=C(C=C1)C(=O)CC(=O)C1=CC=C(C=C1)C(C)(C)C
Eligibility criteria:

        DISEASE CHARACTERISTICS:

          -  Histologically confirmed nasopharyngeal carcinoma (NPC)

               -  Metastatic disease

               -  WHO type II/III disease

          -  Measurable disease

          -  Meets 1 of the following criteria:

               -  Progression on one or more lines of polychemotherapy for treatment of metastatic
                  disease

               -  Failed non-myeloablative hematopoietic stem cell transplant

          -  No active CNS metastases

        PATIENT CHARACTERISTICS:

          -  ECOG performance status 0-2

          -  Life expectancy > 3 months

          -  Hemoglobin ≥ 8.5 g/dL

          -  Serum bilirubin ≤ 1.5 times upper limit of normal

          -  ALT or AST ≤ 5 times normal

          -  Creatinine clearance ≥ 40 mL/min

          -  Left ventricular ejection fraction ≥ 45% by MUGA

          -  Corrected DLCO > 50% of predicted

          -  No active or prior gastrointestinal bleeding

          -  No history of adverse reaction to NSAIDs or sensitivity to celecoxib

          -  No cardiac disease, including any of the following:

               -  Symptomatic congestive heart failure

               -  Active angina pectoris

               -  High-risk uncontrolled arrhythmia

               -  Uncontrolled hypertension

          -  No pulmonary disease, including any of the following:

               -  Severe chronic obstructive lung disease

               -  Uncontrolled large pleural effusion

               -  Severe restrictive lung disease

          -  No cerebrovascular accident

          -  No transient ischemic attack

          -  No HIV positivity

          -  No active uncontrolled infection

          -  No symptomatic leukoencephalopathy or other neuropsychiatric abnormalities

          -  Not pregnant or nursing

          -  Negative pregnancy test

        PRIOR CONCURRENT THERAPY:

          -  See Disease Characteristics

          -  Prior celecoxib allowed

          -  At least 28 days since prior chemotherapy

          -  At least 100 days since prior non-myeloablative hematopoietic stem cell transplant

          -  At least 2 months since prior donor lymphocyte infusions

          -  More than 28 days since prior participation in another clinical trial with any
             investigational drugs

          -  No other concurrent experimental drugs

          -  No other concurrent anticancer therapy

          -  No concurrent anticoagulation with warfarin or low molecular weight heparin

          -  No other concurrent nonsteroidal anti-inflammatory drugs (NSAIDs) or aspirin
Clinical trial NCT00500370 (phase 2, status: completed)
Conditions: obesity
ICD codes: E66.8, E66.9, E66.1, O99.214, O99.215, O99.210, O99.211
Drugs: exenatide, placebo
SMILES: N[C@@H](CCCNC(N)=N)C(O)=O, CN1C(=O)C=C(N2CCC[C@@H](N)C2)N(CC2=C(C=CC=C2)C#N)C1=O
Eligibility criteria:

        Inclusion Criteria:

          -  Have a Body Mass Index (BMI) >= 30kg/m^2

        Exclusion Criteria:

          -  Have ever participated in this study previously, or any other study using exenatide
             (AC2993/LY2148568) or GLP-1 analogs

          -  Have participated in an interventional medical, surgical, or pharmaceutical study (a
             study in which an experimental, drug, medical, or surgical treatment was given) within
             30 days of study start (this criterion includes drugs that have not received
             regulatory approval for any indication at the time of study entry)

          -  Diagnosis of diabetes mellitus (other than gestational diabetes), or previous use of
             anti-diabetic medications for > 3 months

          -  Have had a change in prescribed lipid-lowering or blood pressure agents within 4 weeks
             of screening

          -  Used drugs for weight loss (e.g., Xenical [orlistat], Meridia [sibutramine], Acutrim
             [phenylpropanolamine], Accomplia [rimonabant], Alli [low-dose orlistat], or other
             similar over-the-counter weight loss remedies or medications) within 3 months of
             screening

          -  Are actively participating in, or have participated in a formal weight loss program
             within the last 3 months

          -  Have a history of chronic use of drugs that directly affect gastrointestinal motility,
             including, but not limited to Reglan (metoclopramide) and chronic macrolide
             antibiotics

          -  Have been treated with any anti-diabetic medications within 3 months of screening

          -  Are receiving chronic (lasting longer than 2 weeks) systemic glucocorticoid therapy or
             have received such therapy within the 4 weeks immediately prior to study start

          -  Have had bariatric surgery

          -  Have had an organ transplant
Clinical trial NCT00287976 (phase 2, status: unknown status)
Conditions: liver cancer
ICD codes: D13.4, Z85.05, C22.8, C78.7, C22.9, D37.6
Drugs: irinotecan hydrochloride
SMILES: CCC1=C2CN3C(=CC4=C(COC(=O)[C@]4(O)CC)C3=O)C2=NC2=CC=C(OC(=O)N3CCC(CC3)N3CCCCC3)C=C12
Eligibility criteria:

        DISEASE CHARACTERISTICS:

          -  Diagnosis of hepatoblastoma

               -  Refractory or recurrent disease

                    -  Failed prior first-line or second-line treatment

               -  Metastatic disease allowed

          -  Measurable disease, defined as ≥ 1 unidimensionally measurable lesion ≥ 20 mm by
             conventional techniques OR ≥ 10 mm by spiral CT scan

               -  Elevated serum alpha-fetoprotein (AFP) allowed

          -  No hepatocellular carcinoma

        PATIENT CHARACTERISTICS:

          -  Lansky performance status 50-100% in patients ≤ 10 years of age OR Karnofsky
             performance status 50-100% in patients > 10 years of age

          -  Life expectancy > 8 weeks

          -  Hemoglobin > 8 g/dL

          -  Absolute neutrophil count > 1,000/mm^3

          -  Platelet count > 100,000/mm^3

          -  Serum bilirubin ≤ 2 times normal

          -  AST/ALT ≤ 2 times normal

          -  Serum creatinine ≤ 3 times normal

          -  Normal metabolic parameters (i.e., serum electrolytes, glucose, calcium, and
             phosphate)

          -  Not pregnant or nursing

          -  No severe uncontrolled infection or enterocolitis

        PRIOR CONCURRENT THERAPY:

          -  Recovered from toxicity of prior therapy

          -  No chemotherapy within 3 weeks prior to study entry

          -  No prior irinotecan

          -  No other concurrent anticancer therapy
Clinical trial NCT01423604 (phase 2, status: completed)
Conditions: pancreatic cancer
ICD codes: C25.3
Drugs: capecitabine, ruxolitinib, placebo
SMILES: [H][N]1([H])[C@@H]2CCCC[C@H]2[N]([H])([H])[Pt]11OC(=O)C(=O)O1, N#CC[C@H](C1CCCC1)N1C=C(C=N1)C1=C2C=CNC2=NC=N1, CN1C(=O)C=C(N2CCC[C@@H](N)C2)N(CC2=C(C=CC=C2)C#N)C1=O
Eligibility criteria:

        Inclusion Criteria:

          -  18 years of age or older

          -  Diagnosis of metastatic pancreatic cancer; subjects must have had measurable, or
             evaluable disease that was histologically confirmed

          -  Karnofsky performance status of ≥ 60

          -  Subjects must have failed 1st-line gemcitabine treatment for metastatic pancreatic
             cancer:

             o An alternate chemotherapeutic agent was an acceptable substitute as 1st-line therapy
             in the event that the subject was intolerant to or ineligible to receive gemcitabine

          -  ≥ 2 weeks elapsed from the completion of previous chemotherapy, and subjects must have
             recovered or been at new stable baseline from any related toxicities

        Exclusion Criteria:

          -  More than 1 prior chemotherapy regimen (not including adjuvant therapy) for metastatic
             disease

          -  Evidence of central nervous system (CNS) metastases (unless stable for > 3 months) or
             history of uncontrolled seizures

          -  Ongoing radiation therapy or prior radiation therapy administered as a second-line
             treatment

          -  Other active malignancy except basal or squamous carcinoma of the skin

          -  Inability to swallow food or any condition of the upper GI tract that precluded
             administration of oral medications

          -  Inadequate renal, hepatic and bone marrow function demonstrated by clinical
             observations and/or laboratory assessments
Clinical trial NCT00034827 (phase 2, status: completed)
Conditions: colorectal neoplasms, breast neoplasms, carcinoma, non-small-cell lung, pancreatic neoplasms
ICD codes: C05.2, C10.0, C16.0, C16.4, C17.0, C17.1, C17.2, C79.81, D24.1, D24.2, D24.9, D49.3, C44.501, D48.60, D02.20, D02.21, D02.22, C25.3
Drugs: ci-1040
SMILES: OC(=NOCC1CC1)C1=C(NC2=C(Cl)C=C(I)C=C2)C(F)=C(F)C=C1
Eligibility criteria:

        Inclusion Criteria:

          -  Patients who are at least 18 years or older who have pathological or hiostological
             confirmation of colorectal, nonsmall cell lung cancer, breast, or pancreas cancer.

          -  No more than 1 prior chemo for lung or colon cancer, no more than 2 for breast no
             prior chemotherapy for pancreas cancer.

          -  Original or recent tumor tissue must be available.

          -  Patients must have been off prior chemoptherapy for 4 weeks and radiation for 3 weeks.

          -  Patients must have adequate renal, liver, and bone marrow function, not have serious
             infection or life-threatening illness (unrelated to tumor).

          -  Must be able to swallow capsules and not have gastrointestinal disorders that may
             affect absorption of the drug.

        Exclusion Criteria:

          -  Unstable medical condition

          -  prior chemotherapy within 4 week of screening

          -  series infection

          -  other tumor types

          -  ECOG performance status of 3 or 4.
Clinical trial NCT01275469 (phase 2, status: completed)
Conditions: impaired glucose tolerance, abdominal obesity
ICD codes: R73.02, A42.1, G43.D1, I77.811, R10.815, R10.816, R10.817, R10.84
Drugs: gft505 80mg, placebo
SMILES: CSC1=CC=C(C=C1)C(=O)\C=C\C1=CC(C)=C(OC(C)(C)C(O)=O)C(C)=C1, CN1C(=O)C=C(N2CCC[C@@H](N)C2)N(CC2=C(C=CC=C2)C#N)C1=O
Eligibility criteria:

        Inclusion Criteria:

          -  Male or post-menopausal female.

          -  Waist circumference ≥94cm for male, ≥ 80cm for female.

          -  Fasting Plasma Glucose (FPG) between 110 and 126 mg/dl (between 6.1 and 7.0 mmol/l)
             within 6 months prior to the screening visit.

          -  2-hour glycaemia at OGTT (2hr after a 75g oral glucose load) ≥140 mg/dL (7.8 mmol/l).

        Exclusion Criteria:

          -  Body Mass Index (BMI) ≥ 40 kg/m².

          -  Blood Pressure > 160 / 95 mmHg.

          -  Known Type I or type II Diabetes Mellitus.

          -  Glycated haemoglobin (HbA1c) >7%.

          -  A fasting TG > 400mg/dl and a LDL-C > 220mg/dl.
Clinical trial NCT00728949 (phase 2, status: completed)
Conditions: metastatic breast cancer
ICD codes: C79.81, D24.1, D24.2, D24.9, D49.3, C44.501, D48.60
Drugs: tamoxifen, anastrozole, letrozole, exemestane, fulvestrant
SMILES: OC1=CC=C(C=C1)C1=C(C(=O)C2=CC=C(OCCN3CCCCC3)C=C2)C2=C(S1)C=C(O)C=C2, CC(C)(C#N)C1=CC(=CC(CN2C=NC=N2)=C1)C(C)(C)C#N, N#CC1=CC=C(C=C1)C(N1C=NC=N1)C1=CC=C(C=C1)C#N, CC(C)(C#N)C1=CC(=CC(CN2C=NC=N2)=C1)C(C)(C)C#N, [H][C@@]12CC[C@H](O)[C@@]1(C)CC[C@]1([H])C3=CC=C(O)C=C3C[C@@H](CCCCCCCCCS(=O)CCCC(F)(F)C(F)(F)F)[C@@]21[H]
Eligibility criteria:

        Inclusion Criteria:

          -  The patient has histologically or cytologically-confirmed invasive breast cancer,
             which at the time of study entry is either stage III (locally advanced) disease not
             amenable to curative therapy or stage IV disease. Histological confirmation of
             recurrent/metastatic disease is not required if clinical evidence of stage IV disease
             recurrence is available

          -  Tumors are positive for estrogen receptors (ER), progesterone receptors (PgR), or both
             (ie, 10% or more of infiltrating cancer cells exhibit nuclear staining for ER and/or
             PgR; positive biochemical test results are also acceptable)

          -  The patient has received prior antiestrogen therapy:

               1. With at least one antiestrogen agent (with or without ovarian suppression)
                  administered for ≥ 3 months in the adjuvant or metastatic setting; and

               2. Experienced disease progression while on or within 12 months after receiving the
                  last dose of endocrine therapy

          -  The patient is postmenopausal and/or meets at least one of the following criteria:

               1. Age ≥ 18 years with an intact uterus and amenorrhea for ≥ 12 months, with
                  estradiol and/or follicle-stimulating hormone (FSH) values in the postmenopausal
                  range

               2. History of bilateral oophorectomy

               3. History of bilateral salpingo-oophorectomy

               4. History of radiation castration and amenorrheic for ≥ 3 months

          -  The patient has fasting serum glucose < 120 mg/dL or below the ULN

        Exclusion Criteria:

          -  The patient has received more than two regimens of prior chemotherapy in the
             metastatic (or locally advanced and inoperable breast cancer) and adjuvant setting

          -  The patient has poorly controlled diabetes mellitus. Patients with a history of
             diabetes mellitus are allowed to participate, provided that their blood glucose is
             within normal range (fasting glucose at study entry < 120 mg/dL or below ULN) and that
             they are on a stable dietary and/or therapeutic regimen for this condition

          -  The patient is known to be positive for infection with the human immunodeficiency
             virus
Clinical trial NCT00241371 (phase 2, status: terminated)
Conditions: multiple myeloma
ICD codes: C90.01, C90.02, C90.00
Drugs: clofarabine
SMILES: [H][C@@]12C[C@@H](C)[C@](O)(C(=O)CO)[C@@]1(C)C[C@H](O)[C@@]1(F)[C@@]2([H])CCC2=CC(=O)C=C[C@]12C
Reason stopped: 
    no response seen in patients
  
Eligibility criteria:

        Inclusion Criteria:

          1. Multiple myeloma diagnosed by standard criteria.

          2. Measurable levels of monoclonal protein in serum (>= 0.5 g/dL) or urine (>= 0.2 g/24
             hr).

          3. At least 1 prior therapies for multiple myeloma with documented evidence of
             progression on the most recent treatment.

          4. Age 18 years or older.

          5. ECOG performance status <= 2.

          6. Acceptable organ and marrow function as defined below:

               -  Hemoglobin >= 8 gm/dL

               -  Absolute neutrophil count >= 1,000/mm3

               -  Platelets >= 50,000/mm3

               -  Total bilirubin <= 2.5 X institutional upper limit of normal

               -  AST, ALT <= 2.5 X institutional upper limit of normal

               -  Creatinine 1.5 x institutional upper limit of normal

               -  Normal cardiac function as determined by standard institutional methods

          7. Women of child bearing potential must agree to use adequate contraception prior to
             study entry and for the duration of study.

          8. Ability to understand and the willingness to sign a written informed consent document.

        Exclusion Criteria:

          1. Receiving any other investigational agents.

          2. Receiving concurrent steroids with a dose equivalent of prednisone of >= 150 mg/month.

          3. Pregnant or nursing.

          4. Active systemic infection considered opportunistic, life threatening or clinically
             significant at the time of treatment.

          5. Severe concurrent disease, including severe insulin-dependent diabetes, uncontrolled
             hypertension, transient ischemic attacks, uncontrolled symptomatic coronary artery
             disease, or symptomatic CNS involvement or psychiatric illness/social situations that
             would limit compliance with study requirements.

          6. History of other malignancy except for basal cell or squamous cell carcinoma of the
             skin or carcinoma in situ of the cervix or breast unless the subject has been off
             treatment and free from disease for >= 3 years.